---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107740"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:01:56.686314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025

## Summary
- Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.
- Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.
- Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.
- Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.
- GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025.

## SEC filing metadata
- accession: 0001104659-25-107740
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/0001104659-25-107740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107740
- JSON: https://secwatch.observer/filing/0001104659-25-107740.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.